Amarin Corporation plc (NASDAQ: AMRN) Q4 2019 Earnings Conference Call February 25, 2020 Corporate participants: Elisabeth Schwartz -- Senior Director of Investor Relations John
Amarin Corporation plc (NASDAQ: AMRN) Q4 2019 Earnings Call Transcript
Categories
pharmaceuticals
It’s time to see Teva Pharmaceuticals (TEVA) from a different perspective
Shares of Teva Pharmaceuticals (NYSE: TEVA) fell to a new low this month as markets across the world continued to be battered
Hopes high for Mylan’s Upjohn merger even as epidemic mars short-term prospects
Drugmaker Mylan (NASDAQ: MYL) is all set for a transformation with its planned merger with Upjohn, the generic medicine business of Pfizer
Why investors need to take note as Veru Inc transforms into a prostate cancer firm
According to the American Cancer Society, prostate cancer is the second most common form of cancer among men in the US, affecting almost
Catalyst Pharmaceutical (CPRX): Q4 2019 Earnings Snapshot
-- Catalyst Pharmaceutical (NASDAQ: CPRX) reported its fourth-quarter 2019 earnings of $0.07 per share versus $0.10 per share expected. -- Total revenue
CorMedix (NYSE: CRMD): Q4 2019 Earnings Snapshot
-- CorMedix Inc. (NYSE: CRMD) reported a fourth-quarter 2019 loss of $0.21 per share versus a loss of $0.24 per share expected.
AcelRx Pharmaceuticals (ACRX) Q4 2019 Earnings Snapshot
-- Specialty pharmaceutical company AcelRx Pharmaceuticals (NASDAQ: ACRX) reported fourth quarter 2019 loss of $0.18 per share vs. expected loss of $0.20 per
Achieve Life Sciences (ACHV): Q4 2019 Earnings Snapshot
-- Achieve Life Sciences (NASDAQ: ACHV) reported Q4 2019 net loss of $3.2 million, or $0.30 per share, compared to a loss
Neos Therapeutics (NASDAQ: NEOS): Q4 2019 Earnings Snapshot
-- Neos Therapeutics Inc. (NASDAQ: NEOS) reported a fourth-quarter 2019 loss of $0.07 per share versus a loss of $0.03 per share
Fresh hope for Covid-19 patients as AbbVie (ABBV) leads studies on HIV drug
For some of the leading drugmakers, currently, the first priority is to find an effective treatment for Covid-19, which was declared a
Dynavax Technologies Corporation (NASDAQ: DVAX): Q4 2019 Earnings Snapshot
-- Biopharmaceutical company Dynavax Technologies Corporation (NASDAQ: DVAX) reported a net loss of $36.8 million $0.44 per share for the fourth quarter
Novavax (NVAX) posts wider-than-expected loss in Q4
Novavax Inc. (NASDAQ: NVAX) reported a narrower loss for the fourth quarter of 2019 helped by higher revenue and lower expenses. The
Avid Bioservices (CDMO) Q3 2020 Earnings Snapshot
-- Avid Bioservices (NASDAQ: CDMO) reported a loss of $0.## per share for its third quarter of 2020 vs. expected loss of
Sunesis Pharmaceutical (SNSS): Q4 2019 Earnings Snapshot
Image for representation (Photo by Drew Hays on Unsplash) — Sunesis Pharmaceuticals (NASDAQ: SNSS) reported loss of $0.05 per share in the fourth quarter
Catabasis Pharmaceuticals (NASDAQ: CATB): Q4 2019 Earnings Snapshot
-- Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) reported a net loss of $6.6 million or $0.55 per share for the fourth quarter of
Akebia Therapeutics (AKBA) Q4 2019 Earnings Snapshot
-- Akebia Therapeutics (NASDAQ: AKBA) reported fourth quarter 2019 loss of $0.79 per share vs. expected loss of $0.47 per share. --
Matinas BioPharma (MTNB): Q4 2019 Earnings Snapshot
Image for representation (Photo by Drew Hays on Unsplash) — Matinas BioPharma (NYSE: MTNB) reported loss of $0.04 per share in the fourth quarter
Aurinia Pharmaceuticals (NASDAQ: AUPH): Q4 2019 Earnings Snapshot
-- Aurinia Pharmaceuticals (NASDAQ: AUPH) reported a fourth-quarter 2019 loss of $0.78 per share versus a loss of $0.14 per share expected.
Stock Analysis: GW Pharma (GWPH) offers irresistible upside potential
For GW Pharmaceuticals (NASDAQ: GWPH), the main growth strategy for the current fiscal year is to expand its product pipeline beyond Epidiolex,
Arbutus Biopharma (ABUS): FY19 Earnings Snapshot
-- Arbutus Biopharma Corporation (NASDAQ:ABUS) reported a net loss of $164.9 million or $2.89 per share for fiscal 2019, compared to a
BioCryst Pharmaceuticals (BCRX) Q4 2019 Earnings Snapshot
-- BioCryst Pharmaceuticals (NASDAQ: BCRX) reported a loss of $0.02 per share for the fourth quarter of 2019 vs. expected loss of